Education
About Us
Working with TipRanks
Follow Us
Keros Therapeutics (KROS)
NASDAQ:KROS
Total Valuation
Keros Therapeutics has a market cap or net worth of $595.42M. The enterprise value is $13.33M.
Market Cap$595.42M
Enterprise Value$13.33M
Share Statistics
Keros Therapeutics has 40,615,414 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding40,615,414
Owned by Insiders22.43%
Owned by Institutions35.66%
Financial Efficiency
Keros Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -35.77%.
Return on Equity (ROE)-0.33
Return on Assets (ROA)-0.30
Return on Invested Capital (ROIC)-35.77%
Return on Capital Employed (ROCE)-0.36
Revenue Per Employee21.78K
Profits Per Employee-1.15M
Employee Count163
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Keros Therapeutics is -3.16. Keros Therapeutics’s PEG ratio is -0.81.
PE Ratio-3.16
PS Ratio0.00
PB Ratio0.96
Price to Fair Value1.04
Price to FCF-3.41
Price to Operating Cash Flow-3.42
PEG Ratio-0.81
Income Statement
In the last 12 months, Keros Therapeutics had revenue of 3.55M and earned -187.35M in profits. Earnings per share was -5.00.
Revenue3.55M
Gross Profit2.32M
Operating Income-210.83M
Pretax Income-187.05M
Net Income-187.35M
EBITDA-185.82M
Earnings Per Share (EPS)-5.00
Cash Flow
In the last 12 months, operating cash flow was -160.87M and capital expenditures -1.93M, giving a free cash flow of -162.80M billion.
Operating Cash Flow-160.87M
Free Cash Flow-162.80M
Free Cash Flow per Share-4.01
Dividends & Yields
Keros Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.76
52-Week Price Change-69.56%
50-Day Moving Average13.13
200-Day Moving Average31.15
Relative Strength Index (RSI)61.41
Average Volume (3m)761.87K
Important Dates
Keros Therapeutics upcoming earnings date is Jul 31, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateJul 31, 2025
Ex-Dividend Date―
Financial Position
Keros Therapeutics as a current ratio of 21.45, with Debt / Equity ratio of 3.30%
Current Ratio21.45
Quick Ratio21.45
Debt to Market Cap<0.01
Net Debt to EBITDA2.91
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Keros Therapeutics has paid 300.00K in taxes.
Income Tax300.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Keros Therapeutics EV to EBITDA ratio is -0.28, with an EV/FCF ratio of -0.32.
EV to Sales14.53
EV to EBITDA-0.28
EV to Free Cash Flow-0.32
EV to Operating Cash Flow-0.32
Balance Sheet
Keros Therapeutics has $559.93M in cash and marketable securities with $18.86M in debt, giving a net cash position of -$541.07M billion.
Cash & Marketable Securities$559.93M
Total Debt$18.86M
Net Cash-$541.07M
Net Cash Per Share-$13.32
Tangible Book Value Per Share$15.27
Margins
Gross margin is 74.23%, with operating margin of -5938.96%, and net profit margin of -5277.55%.
Gross Margin74.23%
Operating Margin-5938.96%
Pretax Margin-5269.10%
Net Profit Margin-5277.55%
EBITDA Margin-5234.48%
EBIT Margin-5269.10%
Analyst Forecast
The average price target for Keros Therapeutics is $26.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$26.50
Price Target Upside77.26% Upside
Analyst ConsensusModerate Buy
Analyst Count10
Revenue Growth Forecast91657.69%
EPS Growth Forecast97.21%